Mesoblast Limited

MSB.AX·ASX·Healthcare
Compare
2.1700+0.0700 (+3.33%)today
At close: Nov 5, 4:10 PM AEDT · May be delayed up to 20 min · AUD

Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close2.1000
Open2.1200
Day range2.07502.2000
52-week range1.73503.3100
Off day high−1.36%
Off 52-week high−34.44%
Volume2.95M
Avg. volume (3M)3.12M
Market cap2.82B
EPS (TTM)-0.0700
Forward P/E104.88
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.91
Shares outstanding1.30B
Short interest—
Earnings dateAug 26, 2026
Analyst target3.5733
Profit margin−47.82%

Against its peers

Compare in full ›
MSB.AX SLDB 7776.T 4880.T LCTX VCEL
Market cap 2.82B 699.11M 6.78B 5.76B 260.49M 2.33B
P/E (TTM) — — — 58.4 — 96.8
Forward P/E 104.9 -3.8 — 16.1 -7.5 53.8
Price/book 3.5 2.9 3.0 1.0 4.3 6.3
Dividend yield — — — — — —
1-year change −12.86% +54.69% −57.71% −42.83% −40.46% +10.46%
Today +3.33% +3.82% −4.97% +3.94% +1.98% +10.68%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.

Latest news

All MSB.AX news ›
The Motley Fool Australia·Positive

Should I buy Cochlear and Mesoblast shares with $5,000?

These two companies are at different stages of their growth journeys. Here's which I'd choose for a long-term investment. Her work focuses on making complex financial ideas clear, practical, and engaging for everyday investors. She has a…

The Motley Fool Australia·Positive

Why are Mesoblast shares racing 15% higher today?

Find out what caught investor interest. Samantha Menzies is a writer and editor with close to 20 years' experience covering finance, investing, business and property in Australia and the UK. She has held senior editorial roles at Yahoo…

Seeking Alpha·Positive

Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain

Mesoblast's Ryoncil provides commercial validation for its cell-therapy platform while helping finance additional development. Learn more about MESO stock here. - Mesoblast's Ryoncil provides commercial validation for its cell-therapy…

The Motley Fool Australia·

Buy, hold, sell: Mesoblast, PLS, and SEEK shares

Bell Potter has given its verdict on these shares this week. If you are in the market for some new portfolio additions, it could be worth seeing what the team at Bell Potter is saying about the three ASX shares in this article. Does the…

Stock Titan·

Mesoblast submits three ASX securities notices

The notices cover securities cessation; issue, conversion or payment up of unquoted equity; and an application for securities quotation. Mesoblast submits three ASX securities notices Sentiment and the balance of points Rhea-AI Sentiment…

From the 4Search news index, newest first.

In the news

18mentions in 30 days
18with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance